Resolution of refractory macular edema because of branch retinal vein occlusion after ozurdex implantation.
To report a case of a woman with a branch vein occlusion and macular edema refractory to grid laser, intravitreal bevacizumab, pars plana vitrectomy with sheathotomy of the arteriovenous branch site, and intravitreal triamcinolone, who had complete resolution of fluid after injection of a dexamethasone intravitreal implant (DEX implant, Ozurdex; Allergan, Inc, Irvine, CA). A 75-year-old woman with a branch vein occlusion and macular edema was treated with grid laser, intravitreal bevacizumab, pars plana vitrectomy with sheathotomy, and intravitreal triamcinolone. Neither edema nor vision improved. She was treated with an Ozurdex intravitreal implant. One month after Ozurdex intravitreal implantation, the patient's visual acuity and edema had improved dramatically. The macula remained flat until 5 months after injection when the edema returned and a second Ozurdex was injected. One month later, the macular edema was significantly less and visual acuity had improved to 20/50 with pinhole. Ozurdex may be effective in reducing macular edema because of a branch retinal vein occlusion in eyes refractory to multiple other treatments.